Document is current
Any future updates will be listed below
-
Authors
Dobson, Connor S.
Reich, Anna N.
Gaglione, Stephanie
Smith, Blake E. https://orcid.org/0000-0001-9878-8198
Kim, Ellen J.
Dong, Jiayi https://orcid.org/0000-0003-4028-1057
Ronsard, Larance https://orcid.org/0000-0002-5307-1940
Okonkwo, Vintus
Lingwood, Daniel
Dougan, Michael
Dougan, Stephanie K. https://orcid.org/0000-0002-2263-363X
Birnbaum, Michael E. https://orcid.org/0000-0002-2281-3518
-
Funding
Funding for this research was provided by:
U.S. Department of Defense (W81XWH757 18-1-0208)
Damon Runyon Cancer Research Foundation
David and Lucile Packard Foundation
Michelson Prize and Grants
Pfizer
Pew Charitable Trusts
U.S. Department of Health & Human Services | National Institutes of Health (DP2AI158126, P30CA14051, T32 GM007753, R01AI153098, R01AI137057)
Cancer Research Institute
National Research Foundation Singapore
Schmidt Futures
National Science Foundation
Gouvernement du Canada | Canadian Institutes of Health Research
Cancer Research Foundation
- License Information
-
More Information
Article History
Received: 18 September 2021
Accepted: 1 March 2022
First Online: 8 April 2022
Competing interests
: The lentiviral targeting approach in this manuscript is the subject of US patent applications with M.E.B., S.G. and C.S.D. as co-inventors. M.E.B. is a founder, consultant and equity holder of Viralogic Therapeutics and Abata Therapeutics, is an equity holder in 3T Biosciences, has received consulting fees from Repertoire Immune Medicines and has received research funding from Pfizer that partially funded this work. S.K.D. received unrelated research funding from Novartis Pharmaceuticals, Eli Lilly and Company and Bristol-Myers Squibb and is a founder, science advisory board member and equity holder in Kojin. M.D. is a science advisory board member for Neoleukin, has research funding from Novartis and Eli Lilly, has received consulting fees from Tillotts Pharma, ORIC Pharmaceuticals, Partner Therapeutics, SQZ Biotech, AzurRx, Mallinckrodt Pharmaceuticals and Moderna. The remaining authors declare no competing interests.
